Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT8R70G)

• DTT Name: Gonadotropin-releasing hormone receptor (GNRHR) DTT Info
• Gene Name: GNRHR

Molecule-Related Drug & Molecule List

10 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abarelix	DM5WFNP	Prostate cancer	2C82.0	Approved	[1]
Cetrorelix	DMFD9Q6	Ovarian stimulation	LB45.1	Approved	[2]
Degarelix	DM3O8QY	Prostate cancer	2C82.0	Approved	[3]
Elagolix sodium	DMRDUC0	Endometriosis	GA10	Approved	[4]
Ganirelix	DMGMB30	Ovulation dysfunction	5A80	Approved	[5]
Gonadorelin	DMAQ469	Amenorrhea	GA20.0	Approved	[6]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[7]
Nafarelin	DMAHEFY	Endometriosis	GA10	Approved	[8]
Relugolix	DMK7IWL	Prostate cancer	2C82.0	Approved	[9]
Triptorelin	DMTK4LS	Infertility	GB04	Approved	[10]

10 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AEZS-108	DMAYO46	Acute lymphoblastic leukaemia	2A85	Phase 3	[11]
Elagolix	DMB2C0E	Uterine fibroids	2E86.0	Phase 3	[12]
GnRH	DM0LQ94	Female infertility	GA31.Z	Phase 3	[13]
ACYLINE	DM9GRTK	Prostate cancer	2C82.0	Phase 2	[14]
ASP-1707	DME8XD7	Endometriosis	GA10	Phase 2	[15]
KLH-2109	DM40HOY	Endometriosis	GA10	Phase 2	[16]
Ozarelix	DMEGTH1	Prostate disease	GA91	Phase 2	[17]
PEP-223/CoVaccine HT	DMM9L1R	Prostate cancer	2C82.0	Phase 1/2	[13]
Prostate cancer vaccine	DMRSRBL	Prostate cancer	2C82.0	Phase 1/2	[13]
VERU-100	DMYXE9C	Prostate cancer	2C82.0	Phase 1/2	[18]

8 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Antide	DMEO6PR	Prostate hyperplasia	GA90	Discontinued in Phase 2	[19]
Gonadimmune	DM9MEAY	Prostate cancer	2C82.0	Discontinued in Phase 2	[20]
TAK-013	DM0TDZI	Uterine fibroids	2E86.0	Discontinued in Phase 2	[21]
A-75998	DM0DLC1	Hormone deficiency	5A61.1	Discontinued in Phase 1	[22]
NBI-42902	DM4MTPU	Prostate cancer	2C82.0	Discontinued in Phase 1	[23]
Ramorelix	DMVID8E	Esophageal cancer	2B70	Discontinued in Phase 1	[24]
D-21775	DME07ML	Solid tumour/cancer	2A00-2F9Z	Terminated	[13]
D-26344	DMBJAUC	Solid tumour/cancer	2A00-2F9Z	Terminated	[26]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
5-(N,N-hexamethylene)-amiloride	DMC4IUQ	Coronavirus infection	1D92	Preclinical	[25]

48 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AEZS-115	DMULWOG	Solid tumour/cancer	2A00-2F9Z	Investigative	[13]
AN-207	DMRS0LA	Solid tumour/cancer	2A00-2F9Z	Investigative	[13]
antarelix	DM7TOGW	Discovery agent	N.A.	Investigative	[27]
AZALINE B	DMN861Q	Discovery agent	N.A.	Investigative	[14]
detirelix	DMFWDNJ	Discovery agent	N.A.	Investigative	[28]
FD-1	DM7IEL2	Discovery agent	N.A.	Investigative	[25]
furan-1	DMCFEBW	Discovery agent	N.A.	Investigative	[29]
IN-3	DMENHMU	Discovery agent	N.A.	Investigative	[30]
LHRH	DMB4ACY	Endometriosis	GA10	Investigative	[31]
LXT-101	DM0LKPE	Prostate cancer	2C82.0	Investigative	[32]
Org-30850	DMXGA56	Discovery agent	N.A.	Investigative	[33]
PGlu-His-Trp-Ser-His-D-Tyr-Leu-Arg-Pro-Gly-NH2	DMLMTIY	Discovery agent	N.A.	Investigative	[34]
PGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2	DM40PT5	Discovery agent	N.A.	Investigative	[34]
T-98475	DMFKQ1W	Discovery agent	N.A.	Investigative	[21]
WAY-207024	DMJ14NE	Discovery agent	N.A.	Investigative	[35]
[125I]cetrorelix	DM0X824	Discovery agent	N.A.	Investigative	[36]
[4Aph(CO-(C2H4O)3-C2H4-NH-CO-NH-OCH3)5]degarelix	DM86Z4H	Discovery agent	N.A.	Investigative	[37]
[4Aph(CO-NH-(C2H4O)2-C2H5)5]degarelix	DM4IXJA	Discovery agent	N.A.	Investigative	[37]
[4Aph(CO-NH-OCH3)5,D-4Aph(CO-NH-OCH3)6]degarelix	DM57TIU	Discovery agent	N.A.	Investigative	[37]
[4Aph(CO-NH-OCH3)5]degarelix	DM6C8K1	Discovery agent	N.A.	Investigative	[37]
[4Aph(CO-NH-OH)5]degarelix	DMFMB31	Discovery agent	N.A.	Investigative	[37]
[D-4Aph(CO-NH-(C2H4O)2-C2H5)6]degarelix	DMFKTJ8	Discovery agent	N.A.	Investigative	[37]
[D-4Aph(CO-NH-OCH3)6]degarelix	DMR7TEQ	Discovery agent	N.A.	Investigative	[37]
[D-4Aph(CO-NH-OH)6]degarelix	DMMVIX7	Discovery agent	N.A.	Investigative	[37]
[D-Dab(CO-NH-OCH3)3]degarelix	DMEZKX0	Discovery agent	N.A.	Investigative	[37]
[D-Dab(CO-NH-OH)3]degarelix	DMRVPN1	Discovery agent	N.A.	Investigative	[37]
[D-Dap(CO-NH-OCH3)3]degarelix	DM5ZR4S	Discovery agent	N.A.	Investigative	[37]
[D-Dap(CO-NH-OH)3]degarelix	DMS0LFT	Discovery agent	N.A.	Investigative	[37]
[D-Gln3,D-Ncy(isopropyl)7]acyline	DMP1D7Q	Discovery agent	N.A.	Investigative	[14]
[D-Gln3,D-Ncy(SO,isopropyl)7]acyline	DMFAX1Q	Discovery agent	N.A.	Investigative	[14]
[D-Gln3,D-Ncy(SO2,isopropyl)7]acyline	DM3H0CX	Discovery agent	N.A.	Investigative	[14]
[D-Gln3,Ncy(isopropyl)7]acyline	DMMEQ3R	Discovery agent	N.A.	Investigative	[14]
[D-Gln3,Ncy(SO,isopropyl)7]acyline	DM2QDXW	Discovery agent	N.A.	Investigative	[14]
[D-Gln3,Ncy(SO2,isopropyl)7]acyline	DMJSCO7	Discovery agent	N.A.	Investigative	[14]
[D-Ncy(2-naphthyl)1]acyline	DMAFNTL	Discovery agent	N.A.	Investigative	[14]
[D-Ncy(isopropyl)7]acyline	DMVBTAM	Discovery agent	N.A.	Investigative	[14]
[D-Ncy(methyl)10] acyline	DM9TORW	Discovery agent	N.A.	Investigative	[14]
[D-Ncy(methyl)4]acyline	DM63FN5	Discovery agent	N.A.	Investigative	[14]
[D-Ncy(SO,isopropyl)7]acyline	DME9AN4	Discovery agent	N.A.	Investigative	[14]
[D-Ncy(SO,methyl)10]acyline	DMT2X98	Discovery agent	N.A.	Investigative	[14]
[D-Ncy(SO,methyl)4]acyline	DM6HEXG	Discovery agent	N.A.	Investigative	[14]
[Ncy(2-naphthyl)1]acyline	DME6LKY	Discovery agent	N.A.	Investigative	[14]
[Ncy(isopropyl)7]acyline	DM5CS8U	Discovery agent	N.A.	Investigative	[14]
[Ncy(methyl)10]acyline	DM9RC3O	Discovery agent	N.A.	Investigative	[14]
[Ncy(methyl)4]acyline	DMLK8YQ	Discovery agent	N.A.	Investigative	[14]
[Ncy(SO,isopropyl)7]acyline	DMEFIQ9	Discovery agent	N.A.	Investigative	[14]
[Ncy(SO,methyl)10]acyline	DMT8X45	Discovery agent	N.A.	Investigative	[14]
[Ncy(SO,methyl)4]acyline	DM057MP	Discovery agent	N.A.	Investigative	[14]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [2] Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33.
• [3] Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60.
• [4] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [5] Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotrope inhibiti... J Clin Endocrinol Metab. 2007 Sep;92(9):3626-32.
• [6] Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29.
• [7] Clinical pipeline report, company report or official report of Takeda (2009).
• [8] Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin ... Theriogenology. 2009 Apr 15;71(7):1037-45.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [10] Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44.
• [11] Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinicalstudies. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):829-34.
• [12] Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond Engl). 2015 Jan;11(1):19-28.
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256).
• [14] Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032657)
• [16] Clinical pipeline report, company report or official report of Avarx.
• [17] Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9.
• [18] ClinicalTrials.gov (NCT04843319) Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer. U.S.National Institutes of Health.
• [19] Antide (Nal-Lys GnRH antagonist) suppression of pituitary-testicular function and sexual behavior in group-living rhesus monkeys. Physiol Behav. 1991 Aug;50(2):429-35.
• [20] A novel retro-inverso gonadotropin-releasing hormone (GnRH) immunogen elicits antibodies that neutralize the activity of native GnRH. Endocrinology. 2003 Jul;144(7):3262-9.
• [21] Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem. 2008 Jun 26;51(12):3331-48.
• [22] Physicochemical properties of A-75998, an antagonist of luteinizing hormone releasing hormone. J Pharm Sci. 1995 Aug;84(8):953-8.
• [23] Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008 Dec 11;51(23):7478-85.
• [24] Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations. J Cancer Res Clin Oncol. 1993;119(8):457-62.
• [25] Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Mol Pharmacol. 2008 Jun;73(6):1808-15.
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003256)
• [27] Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay. Anal Biochem. 1997 Aug 15;251(1):17-23.
• [28] Inhibition of follicular development by a potent antagonistic analog of gonadotropin-releasing hormone (detirelix). J Clin Endocrinol Metab. 1991 Apr;72(4):927-33.
• [29] Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J Pharmacol Exp Ther. 2003 May;305(2):688-95.
• [30] Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. JClin Endocrinol Metab. 2002 Jul;87(7):3255-62.
• [31] Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J Med Chem. 1998 Oct 22;41(22):4190-5.
• [32] In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats. Regul Pept. 2006 Sep 11;136(1-3):122-9.
• [33] In vivo effects of a potent GnRH antagonist ORG 30850: physiologic evidence that down-regulation of GnRH receptors does not occur. J Soc Gynecol Investig. 1994 Oct-Dec;1(4):290-6.
• [34] Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor. J Med Chem. 2006 Jan 26;49(2):637-47.
• [35] Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2512-5.
• [36] Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding. Mol Endocrinol. 2000 Jul;14(7):1099-115.
• [37] Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43.